Feb. 25, 2023
baxdrostat
oral aldosterone synthase (CYP11B2) inhibitor Ph. I/II for HTN, CKD, primary aldosteronism from in-house screen of aldosterone synthase inhibitors Press release, January 9, 2023 Roche, Basel, CH (Cincor/AstraZeneca)
oral aldosterone synthase (CYP11B2) inhibitor Ph. I/II for HTN, CKD, primary aldosteronism from in-house screen of aldosterone synthase inhibitors Press release, January 9, 2023 Roche, Basel, CH (Cincor/AstraZeneca)